The clinical conundrum of managing relapsed small cell lung cancer

被引：1
|
作者：
Nazha, Bassel [1 ]
Owonikoko, Taofeek K. [1 ]
机构：
[1] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
来源：
CANCER | 2019年 / 125卷 / 07期
关键词：
PHASE-III TRIAL; OPEN-LABEL; 2ND-LINE CHEMOTHERAPY; TOPOTECAN; ETOPOSIDE; EFFICACY; MULTICENTER; RECHALLENGE; IRINOTECAN; AMRUBICIN;
D O I：
10.1002/cncr.31849
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The management of patients with relapsed/refractory small cell lung cancer is a true clinical conundrum. Using a common but challenging clinical scenario, this article discusses treatment considerations and promising emergent data on immune checkpoint inhibitor therapy and targeted therapy.
引用
收藏
页码：1022 / 1026
页数：5
相关论文
共 50 条
  • [21] Is relapsed small-cell lung cancer (SCLC) under treated?
    Nicum, S.
    Ashley, S.
    O'Brien, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 377 - 377
  • [22] EFFICACY OF AMRUBICIN IN PATIENTS WITH REFRACTORY RELAPSED SMALL CELL LUNG CANCER
    Wakuda, Kazushige
    Kenmotsu, Hirotsugu
    Oyakawa, Takuya
    Hisamatsu, Yasushi
    Kimura, Madoka
    Tokito, Takaaki
    Imai, Hisao
    Akamatsu, Hiroaki
    Ono, Akira
    Shukuya, Takehito
    Taira, Tetsuhiko
    Naito, Tateaki
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S493 - S494
  • [23] Three Weekly Irinotecan for Refractory/Relapsed Small Cell Lung Cancer
    Nutalapati, S.
    Yan, D.
    Morgan, R.
    Chauhan, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1188 - S1188
  • [24] Phase II Trial of Vinflunine in Relapsed Small Cell Lung Cancer
    Spigel, David R.
    Hainsworth, John D.
    Lane, Cassie M.
    Clark, Bobby
    Burris, Howard A., III
    Greco, F. Anthony
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : 874 - 878
  • [25] Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer
    Riemsma, Rob
    Simons, Jean P.
    Bashir, Zahid
    Gooch, Caroline L.
    Kleijnen, Jos
    BMC CANCER, 2010, 10
  • [26] LURBINECTEDIN IS SAFE AND ACTIVE IN RELAPSED SMALL-CELL LUNG CANCER
    不详
    CANCER DISCOVERY, 2020, 10 (06) : 757 - 757
  • [27] Second-line chemotherapy for relapsed small cell lung cancer
    Ebi, N
    Kubota, K
    Nishiwaki, Y
    Hojo, F
    Matsumoto, T
    Kakinuma, R
    Ohmatsu, H
    Sekine, I
    Yokosaki, M
    Gotoh, K
    Yamamoto, H
    Kodama, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (03) : 166 - 169
  • [28] Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer
    Rob Riemsma
    Jean P Simons
    Zahid Bashir
    Caroline L Gooch
    Jos Kleijnen
    BMC Cancer, 10
  • [29] Relapsed small cell lung cancer: treatment options and latest developments
    Asai, Nobuhiro
    Ohkuni, Yoshihiro
    Kaneko, Norihiro
    Yamaguchi, Etsuro
    Kubo, Akihito
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (02) : 69 - 82
  • [30] Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
    Farago, Anna F.
    Yeap, Beow Y.
    Stanzione, Marcello
    Hung, Yin P.
    Heist, Rebecca S.
    Marcoux, J. Paul
    Zhong, Jun
    Rangachari, Deepa
    Barbie, David A.
    Phat, Sarah
    Myers, David T.
    Morris, Robert
    Kem, Marina
    Dubash, Taronish D.
    Kennedy, Elizabeth A.
    Digumarthy, Subba R.
    Sequist, Lecia V.
    Hata, Aaron N.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Lawrence, Michael S.
    Shaw, Alice T.
    Mino-Kenudson, Mari
    Dyson, Nicholas J.
    Drapkin, Benjamin J.
    CANCER DISCOVERY, 2019, 9 (10) : 1372 - 1387
12345